ClinicalTrials.gg
CompletedNCT05863130Updated Jun 29, 2026Results posted

A Study in Healthy Men to Test How BI 764198 is Processed in the Body

A Phase 1 interventional study of BI 764198 (C-14) (approach 1) and BI 764198 (C-14) (approach 2) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the basic pharmacokinetics of BI 764198 and its metabolites, total radioactivity including mass balance, excretion pathways and metabolism following oral administration to healthy male volunteers of a single oral dose of BI 764198 (C-14) in i) a classical hADME approach and ii) a hADME microtracer approach.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 65 years (inclusive)
  • of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 45 to 90 mmHg, or pulse rate outside the range of 40 to 100 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders Further exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BI 764198 (C-14) (approach 1)

    Drug: BI 764198 (C-14) (approach 1)

  • Experimental
    BI 764198 (C-14) (approach 2)

    Drug: BI 764198 (C-14) (approach 2)

Interventions

06

What researchers measure

Primary outcomes

  1. Mass Balance Recovery of Total Radioactivity in Urine and Faeces: Amount Excreted Within the Time Interval From 0 to the Time of the Last Quantifiable Data Point as a Percentage of the Administered Dose (fe0-tz) for Urine and Faeces.

    Urine: Within 2 hours before drug administration, and at 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours post-drug administration. Feces: up to 48 hours (feces) before drug administration, and at 24, 48, 72, 96, 120, 144, 168, and 192 hours post-drug administration. If warranted, further 24-hour collections at trial site were performed at 365-389, 533-557-, and 701-725-hours post-administration depending on participants fulfilling the radioactivity recovery criteria.

    Time frame: Urine and feces sample collection: 48 hours before and up to 725 hours after drug administration. The details are mentioned in the description section.

Secondary outcomes

  1. AUC0-tz, Area Under the Concentration-time Curve of [14C]-BI 764198-EQ Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.

    For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points. The measurements of \[14C\]-BI 764198-EQ concentration is adjusted or standardized to reflect a "bioequivalent" form.

    Time frame: Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.

  2. AUC0-tz, Area Under the Concentration-time Curve of BI 764198 Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.

    For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points.

    Time frame: Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.

  3. Cmax, Maximum Measured Concentration of [14C]-BI 764198-EQ in Plasma After Single Oral Administration of [14C]BI 76418.

    For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points. The measurements of \[14C\]-BI 764198-EQ concentration is adjusted or standardized to reflect a "bioequivalent" form. This standardization ensures that the data can be accurately compared to the unlabeled BI 764198.

    Time frame: Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.

  4. Cmax, Maximum Measured Concentration of BI 76418 in Plasma After Single Oral Administration of [14C]BI 76418.

    For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points.

    Time frame: Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.

07

Results

Posted Jun 3, 2026
Limitations and caveats
An additional cohort (2b) was introduced due to errors in plasma samples from the first 8 participants in cohort 2a, preventing reliable metabolite profiling. Cohort 2b received the same treatment to enable proper profiling. The assessment schedule for cohort 2b was abbreviated, release criteria were not applied, and data from cohorts 2a and 2b were pooled for analysis.

Participant flow

This open-label, non randomised, single-dose, single-period, two-arm phase I trial investigates the mass balance, metabolism, and pharmacokinetics of a single dose of BI 764198 in healthy males. Study arm 1 uses a classical hADME approach, while study arm 2 uses a microtracer approach and is divided into two cohorts (2a and 2b). Participants were allocated in a 1:2 ratio based on availability.

Participant flow — Overall Study
MilestoneCohort 1: Classical hADMECohort 2: Microtracer hADME
Started816
Completed816
Not completed00

Outcome measures

PrimaryMass Balance Recovery of Total Radioactivity in Urine and Faeces: Amount Excreted Within the Time Interval From 0 to the Time of the Last Quantifiable Data Point as a Percentage of the Administered Dose (fe0-tz) for Urine and Faeces.

Urine: Within 2 hours before drug administration, and at 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, and 192 hours post-drug administration. Feces: up to 48 hours (feces) before drug administration, and at 24, 48, 72, 96, 120, 144, 168, and 192 hours post-drug administration. If warranted, further 24-hour collections at trial site were performed at 365-389, 533-557-, and 701-725-hours post-administration depending on participants fulfilling the radioactivity recovery criteria.

Time frame:
Urine and feces sample collection: 48 hours before and up to 725 hours after drug administration. The details are mentioned in the description section.
Reported as:
Geometric mean · Percentage of dose excreted
Mass Balance Recovery of Total Radioactivity in Urine and Faeces: Amount Excreted Within the Time Interval From 0 to the Time of the Last Quantifiable Data Point as a Percentage of the Administered Dose (fe0-tz) for Urine and Faeces.
Percentage of dose excretedCohort 1: Classical hADMECohort 2: Microtracer hADME
Urine73.7 ± 6.2373.2 ± 6.04
Faeces22.9 ± 10.722.4 ± 10.6
SecondaryAUC0-tz, Area Under the Concentration-time Curve of [14C]-BI 764198-EQ Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.

For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points. The measurements of \[14C\]-BI 764198-EQ concentration is adjusted or standardized to reflect a "bioequivalent" form.

Time frame:
Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.
Reported as:
Geometric mean · Hours * nanomoles per liter (h*nmol/L)
AUC0-tz, Area Under the Concentration-time Curve of [14C]-BI 764198-EQ Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.
Hours * nanomoles per liter (h*nmol/L)Cohort 1: Classical hADMECohort 2: Microtracer hADME
AUC0-tz, Area Under the Concentration-time Curve of [14C]-BI 764198-EQ Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.27500 ± 11.137600 ± 24.4
SecondaryAUC0-tz, Area Under the Concentration-time Curve of BI 764198 Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.

For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points.

Time frame:
Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.
Reported as:
Geometric mean · Hours * nanomoles per liter (h*nmol/L)
AUC0-tz, Area Under the Concentration-time Curve of BI 764198 Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.
Hours * nanomoles per liter (h*nmol/L)Cohort 1: Classical hADMECohort 2: Microtracer hADME
AUC0-tz, Area Under the Concentration-time Curve of BI 764198 Over the Time Interval From 0 to the Last Quantifiable Time Point in Plasma After Single Oral Administration of [14C]BI 764198.13200 ± 13.214500 ± 24.6
SecondaryCmax, Maximum Measured Concentration of [14C]-BI 764198-EQ in Plasma After Single Oral Administration of [14C]BI 76418.

For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points. The measurements of \[14C\]-BI 764198-EQ concentration is adjusted or standardized to reflect a "bioequivalent" form. This standardization ensures that the data can be accurately compared to the unlabeled BI 764198.

Time frame:
Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.
Reported as:
Geometric mean · Nanomoles per liter (nmol/L)
Cmax, Maximum Measured Concentration of [14C]-BI 764198-EQ in Plasma After Single Oral Administration of [14C]BI 76418.
Nanomoles per liter (nmol/L)Cohort 1: Classical hADMECohort 2: Microtracer hADME
Cmax, Maximum Measured Concentration of [14C]-BI 764198-EQ in Plasma After Single Oral Administration of [14C]BI 76418.1740 ± 20.71800 ± 16.7
SecondaryCmax, Maximum Measured Concentration of BI 76418 in Plasma After Single Oral Administration of [14C]BI 76418.

For participants in the cohorts 1 and 2a, further samples were collected at 365, 533, and 701 hours only if \[14C\]-radioactivity in plasma post 216 hours after drug administration exceeded the quantification limit at two consecutive points.

Time frame:
Within 3 hours before drug intake, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 365, 533, and 701 hours post-administration.
Reported as:
Geometric mean · nanomole/Liter (nmol/L)
Cmax, Maximum Measured Concentration of BI 76418 in Plasma After Single Oral Administration of [14C]BI 76418.
nanomole/Liter (nmol/L)Cohort 1: Classical hADMECohort 2: Microtracer hADME
Cmax, Maximum Measured Concentration of BI 76418 in Plasma After Single Oral Administration of [14C]BI 76418.1420 ± 19.81450 ± 23.7

Adverse events

Collected over AE collection period: From drug administration until 4 days after drug administration. All-cause mortality: From drug administration up to 31 days after drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Classical hADME0/8 (0%)0/8 (0%)3/8 (37.5%)
Cohort 2a: Microtracer hADME0/8 (0%)0/8 (0%)5/8 (62.5%)
Cohort 2b: Microtracer hADME0/8 (0%)0/8 (0%)5/8 (62.5%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCohort 1: Classical hADMECohort 2a: Microtracer hADMECohort 2b: Microtracer hADME
DiarrhoeaGastrointestinal disorders0/82/80/8
FlatulenceGastrointestinal disorders2/82/80/8
Conjunctival haemorrhageEye disorders0/80/81/8
Abdominal distensionGastrointestinal disorders0/81/80/8
Frequent bowel movementsGastrointestinal disorders0/80/81/8
Influenza like illnessGeneral disorders0/80/81/8
PainGeneral disorders0/80/81/8
Muscle spasmsMusculoskeletal and connective tissue disorders0/80/81/8
DizzinessNervous system disorders1/80/80/8
Depressed moodPsychiatric disorders0/81/80/8

Baseline characteristics

Treated set (TS): The treated set includes all subjects who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(years)Cohort 1: Classical hADMECohort 2: Microtracer hADMETotal
Mean31.6 ± 11.537.3 ± 16.535.4 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Classical hADMECohort 2: Microtracer hADMETotal
Female000
Male81624
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Classical hADMECohort 2: Microtracer hADMETotal
Hispanic or Latino000
Not Hispanic or Latino81624
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Classical hADMECohort 2: Microtracer hADMETotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White81624
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • ICON
    Groningen, 9728 NZ, Netherlands
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Nov 2023, 6 months.

Results were first posted in Jun 2026, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 17, 2023
StartActual
May 3, 2023
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 9, 2023
Results first posted
Jun 3, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05863130
Responsible party
Sponsor
First posted
May 17, 2023
Start date
May 3, 2023
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023
Results posted
Jun 3, 2026
Last update
Jun 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI-764198

Start the discussion